CN1265799C - 含锌化合物和谷氨酰胺类的组合物 - Google Patents
含锌化合物和谷氨酰胺类的组合物 Download PDFInfo
- Publication number
- CN1265799C CN1265799C CN 97109039 CN97109039A CN1265799C CN 1265799 C CN1265799 C CN 1265799C CN 97109039 CN97109039 CN 97109039 CN 97109039 A CN97109039 A CN 97109039A CN 1265799 C CN1265799 C CN 1265799C
- Authority
- CN
- China
- Prior art keywords
- zinc
- glutamines
- glutamine
- effect
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract description 28
- 239000011701 zinc Substances 0.000 title abstract description 28
- 229910052725 zinc Inorganic materials 0.000 title abstract description 28
- 235000004554 glutamine Nutrition 0.000 title abstract description 22
- 150000002309 glutamines Chemical class 0.000 title abstract 5
- 239000002131 composite material Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003752 zinc compounds Chemical class 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims description 26
- 208000025865 Ulcer Diseases 0.000 claims description 10
- 231100000397 ulcer Toxicity 0.000 claims description 10
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 29
- 239000003814 drug Substances 0.000 abstract description 24
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 15
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 15
- 208000008469 Peptic Ulcer Diseases 0.000 abstract description 12
- 208000011906 peptic ulcer disease Diseases 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 11
- 210000002249 digestive system Anatomy 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000003405 preventing effect Effects 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 21
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 19
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 17
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 15
- 229960000905 indomethacin Drugs 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 7
- 230000001079 digestive effect Effects 0.000 description 6
- 206010048259 Zinc deficiency Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 235000003969 glutathione Nutrition 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 4
- 108010044940 alanylglutamine Proteins 0.000 description 4
- 229960002648 alanylglutamine Drugs 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 150000001447 alkali salts Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 4
- -1 fluidizer Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LRGQZEKJTHEMOJ-UHFFFAOYSA-N propane-1,2,3-triol;zinc Chemical compound [Zn].OCC(O)CO LRGQZEKJTHEMOJ-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- DDKJKQVNNATMAD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;zinc Chemical compound [Zn].NCCCC[C@H](N)C(O)=O DDKJKQVNNATMAD-JEDNCBNOSA-N 0.000 description 1
- LQZFQLVBZRVDLJ-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;zinc Chemical compound [Zn].OC(=O)[C@@H](N)CC(O)=O LQZFQLVBZRVDLJ-DKWTVANSSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- HUKGDBBEVQLTMY-KQBMADMWSA-N [Zn].N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O Chemical compound [Zn].N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O HUKGDBBEVQLTMY-KQBMADMWSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004582 acexamic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical group C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229940100888 zinc compound Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- GEVJDDLLVRRIOL-UHFFFAOYSA-L zinc;6-acetamidohexanoate Chemical compound [Zn+2].CC(=O)NCCCCCC([O-])=O.CC(=O)NCCCCCC([O-])=O GEVJDDLLVRRIOL-UHFFFAOYSA-L 0.000 description 1
- XDWXRAYGALQIFG-UHFFFAOYSA-L zinc;propanoate Chemical compound [Zn+2].CCC([O-])=O.CCC([O-])=O XDWXRAYGALQIFG-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及主要由锌化合物和如说明书中式(I)所示的谷氨酰胺类组成的组合物。组合物具有免疫调节、消化系统细胞保护、给机体补充锌和/或谷氨酰胺类的作用;组合物作为预防、控制或治疗消化性溃疡;预防、控制或治疗非甾体抗炎药诱发消化性溃疡;预防、控制或治疗乙醇对消化系统的损害;预防、控制或治疗机体锌缺乏和/或谷氨酰胺类缺乏而引起有关疾病等药物的有效成份。锌化合物和谷氨酰胺类为有效成分,制成一系列药学可接受的组合物。
Description
本发明涉及含有锌化合物和谷氨酰胺类的组合物。组合物主要由药学可接受的锌化合物和如式(I)所示的谷氨酰胺类或者是碱金属、碱土金属盐或锌化合物组成。本组合物具有免疫调节作用、消化系统细胞保护作用、绐机体补充锌的作用和/或补充谷氨酰胺的作用。本组合物作为预防、控制或治疗消化性溃疡药物的有效成份;作为预防、控制或治疗非甾体抗炎药诱发消化性溃疡药物的有效成份;预防、控制或治疗乙醇对消化系统损害药物的有效成份;作为预防、控制或治疗机体锌缺乏而引起有关疾病药物的有效成份;作为预防、控制或治疗机体谷氨酰胺缺乏而引起有关疾病药物的有效成份。锌化合物和谷氨酰胺类及药用辅料,或者其它药物,制成一系列药学可接受的组合物。
谷氨酰胺类化合物,其特征在于式(I)中:
式(I)
R1是H,R2是H时为L-谷氨酰胺;
R1是-COCH3,R2是H时为乙酰谷氨酰胺[N-乙酰-L-谷氨酰胺];
R1是-COCH2CH2NH2,R2是H时为丙氨酰谷氨酰胺[N-丙氨酰-L-谷氨酰胺];
锌是生命元素,属于必需微量元素,在人体中含量仅次于铁而居第二位,具有很重要的营养作用,在1934年就证实锌是人类不可缺少的生命元素,已知锌存在于二百多种酶中,锌与核酸和蛋白质代谢密切相关,在视网膜定位,保持视力和味觉功能,骨骼的正常生长等方面都是必需的,特别是对儿童的生长和发育具有重要作用,提高机体的免疫能力,促进创伤愈合,并能预防或治疗消化性溃疡,预防四氯化碳、乙醇、烷化剂及镉所致肝损害。锌缺乏可致免疫器官发育障碍,并影响体液免疫、细胞免疫、补体系统及机体的天然防御系统,通过补充适量的锌,可使机体的免疫功能恢复。锌化合物已用于镰状细胞性贫血、类风湿性关节炎、在急性组织损伤、烧伤、外科等手术的伤口愈合、锌缺乏症、病毒性感冒、小儿腹泻、肝脏疾病和胃溃疡,促进机体的免疫功能恢复,有一定的治疗作用。
72年临床上就发现锌化合物对消化性溃疡有一定的治疗作用,1976年发现锌化合物对实验性消化溃疡模型具有预防和治疗作用,锌化合物具有提高机体免疫能力和消化系统细胞保护作用;具有生物细胞膜稳定作用,防止肥大细胞脱颗粒,抑制释放出组胺的作用,锌通过金属巯基蛋白和谷胱甘肽的活性,具有清除自由基的作用,维持胃肠道粘膜上皮细胞完整性,防止非甾体抗炎药如:阿司匹林、吲哚美辛等造成胃粘膜屏障的破坏及PGE2和粘液减少的保护作用,加速细胞的分裂和增殖,对损伤部位的修复有促进愈合作用。锌化合物具有抑制胃H+、K+-ATP酶的作用,锌化合物不仅抑制尿素酶,抑制幽门弯曲菌的生长,而且临床治疗也确证了锌化合物对幽门弯曲菌有很好的杀灭作用。已经有四种有机锌化合物类药物[甘草酸锌、醋氨己酸锌、甘油锌和丙氨酰组氨酸锌]用于治疗消化性溃疡疾病。
总之,锌化合物在治疗消化性溃疡时,虽然具有细胞保护作用,但锌离子都是间接起作用,不能直接参与组织细胞的修复和构成,也不能提供修复所需的能量和营养物质。因此现有用于治疗消化性溃疡的锌化合物类药物在治疗机理上存在的一定的缺陷。
本发明的目的,是针对上述现有技术的不足进行改进,提出一种可供药用的组合物,组合物主要由锌化合物和谷氨酰胺类组成,即药学可接受的锌化合物和谷氨酰胺类药学可接受的盐。
68年报道了谷氨酰胺具有预防大鼠的应激性胃粘膜损伤的作用,最近的研究结果改变了长期以来对谷氨胺酰生理作用重要性低估的看法,谷氨胺酰是消化系统主要的营养和能量来源,谷氨酰胺给胃肠道粘膜上皮细胞提供能量,有助于维持胃肠器官代谢,对保护和维护消化系统的器官的结构与功能具有重要的作用,谷氨胺酰为氨基酸、蛋白质的合成提供氮源和能量;参与DNA、RNA前体--嘌呤和嘧啶的合成,提高胃肠粘膜的DNA和蛋白含量以及粘膜厚度,促进损伤部位的修复;为免疫细胞分裂和分泌免疫球蛋白提供氮源和能量,提高胃肠道免疫功能,而被认为是免疫调节剂;能够促进细胞更新和再生,保护胃肠粘膜屏障,维持粘膜形态和结构的完整性;参与谷甘光肽的合成,间接抵抗自由基对生物膜的损害。还有促进大脑发育、提高智力、预防和治疗四氯化碳、乙醇或镉对肝损伤的作用、在急性组织损伤、烧伤、外科手术中发挥一定的作用。谷氨酰胺类单独用于消化性溃疡和或非甾体抗炎药诱发的消化性溃疡治疗效果不理想。
为了实现本发明的目的,本组合物中有效成份之一锌化合物是指:醋酸锌、氯化锌、硫酸锌、磷酸锌、[碱式]碳酸锌、氧化锌、氢氧化锌、乙酰水杨酸锌、吲哚美辛锌、葡萄糖酸锌、构橼酸锌、赖氨酸锌、天门冬氨酸锌、甘草酸锌、甘油锌、丙氨酰组氨酸锌、乙酰氨基己酸锌、对乙酰氨基苯乙酸锌、硬脂酸锌或丙酸锌等药学可接受的锌化合物。
为了实现本发明的目的,本组合物中有效成份之一谷氨酰胺类是指:L-谷氨酰胺、乙酰谷氨酰胺[N-乙酰-L-谷氨酰胺]、丙氨酰谷氨酰胺[N-丙氨酰-L-谷氨酰胺]、谷胱甘肽[γ-L-谷氨酰-L-半胱氨酰基甘氨酸]或者是碱金属、碱土金属盐或锌化合物。
锌化合物和谷氨酰胺类组合物具有免疫调节作用、消化系统细胞保护作用、给机体补充锌和/或补充谷氨酰胺的作用等一系列生理活性。
无水乙醇实验表明:组合物具有消化系统细胞保护作用,具有预防或治疗乙醇对消化系统的损害作用,预防和治疗消化性溃疡的作用,预防和治疗乙醇对粘膜的损害的免疫保护作用。吲哚美辛是非甾体抗炎药物中对粘膜损害作用最强的药物,吲哚美辛实验表明:组合物具有预防或治疗非甾体抗炎药诱发消化性溃疡的作用,组合物的有效成份具有协同的药理作用。
锌化合物和谷氨酰胺类组合物的用途是:作为预防、控制或治疗消化性溃疡药物的有效成份;作为预防、控制或治疗非甾体抗炎药诱发消化性溃疡药物的有效成份;作为预防、控制或治疗乙醇对消化系统损害药物的有效成份;作为预防、控制或治疗机体锌缺乏而引起有关疾病药物的有效成份和/或作为预防、控制或治疗机体谷氨酰胺缺乏而引起有关疾病药物的有效成份。
与锌化合物或谷氨酰胺类单独使用相比,在免疫调节作用、消化系统细胞保护作用、给机体补充锌和/或补充谷氨酰胺作用等方面,锌化合物和谷氨酰胺类组合物的药理作用更加完善、更加全面、更加合理,即具有锌离子的间接的细胞保护作用,也有谷氨酰胺的为胃肠道提供氨源和能量等营养物质的作用,并参与生物合成的直接细胞保护作用,与单个有效成份比较,组合物的有效成份具有协同的药理作用,组合物具有突出的实质性特点和显著的技术进步。
为了实现本发明的目的,将锌化合物和谷氨酰胺类,按照药剂学可接受的方法进行处理,制备成一系列药学上可接受的制剂。
锌化合物和谷氨酰胺类组合物的使用形式是,锌化合物和谷氨酰胺类不加入或者加入如:赋形剂、粘合剂、崩解剂、助流剂、润滑剂、着色剂、矫味剂、甜味剂、稳定剂、控释剂、包衣剂、等渗剂等药用辅料,制成经口或非经口如:供口服、肌肉注射、皮下注射、静脉注射、直肠、阴道和皮肤等使用的固体、半固体和液体等给药形式的组合物如:片剂、包衣片、糖衣片、咀嚼片、口含片、硬胶囊、软胶囊、调释制剂、丸剂、颗粒剂、细粉剂、散剂、溶液剂、口服液、混悬液、乳剂、注射剂[液]、无菌[冻干]粉针、油[水]溶性基质直肠栓剂、油[水]溶性基质阴道栓剂、膜剂、油[水]溶性软膏、硬膏等各种药学可接受的剂型。
主要由锌化合物和谷氨酰胺类组成的组合物,作为有效成份也可含有葡萄糖、果糖、半乳糖、亮氨酸、异亮氨酸、赖氨酸、蛋氨酸、乙酰蛋氨酸、苯丙氨酸、苏氨酸、色氨酸、缬氨酸、瓜氨酸、鸟氨酸、乙酰羟脯氨酸、脯氨酸、甘氨酸、丙氨酸、组氨酸或N-丙氨酰-L-组氨酸或者是碱金属、碱土金属盐或锌化合物、维生素E、米索前列醇、H2受体拮抗剂、质子泵抑制剂、抗酸剂、解热镇痛药、非甾体抗炎药或者金制剂等药物及药用辅料等,制成经口或非经口如:供口服、肌肉注射、皮下注射、静注射脉、直肠、阴道和皮肤等使用的固体、半固体和液体等药学可接受给药形式的组合物,具有免疫调节作用、消化系统细胞保护作用、给机体补充锌作用和给机体补充谷氨酰胺作用,作为预防、控制或治疗消化性溃疡药物的有效成份;作为预防、控制或治疗非甾体抗炎药诱发消化性溃疡药物的有效成份;预防、控制或治疗乙醇对消化系统损害药物的有效成份;作为预防、控制或治疗机体锌缺乏而引起有关疾病药物的有效成份和/或预防、控制或治疗机体谷氨酰胺缺乏而引起有关疾病药物的有效成份。
本组合物每日有效成分的使用量分别是:口服锌化合物为1mg~1000mg[以锌含量计算]和谷氨酰胺类为1mg~90g[以相应的谷氨酰胺类含量:谷氨酰胺、乙酰谷氨酰胺、丙氨酰谷氨酰胺或谷胱甘肽为有效量或总量计算];非经口使用锌化合物为1mg~3000mg[以锌含量计算]和谷氨酰胺为1mg~90g[以相应谷氨酰胺类含量:谷氨酰胺、乙酰谷氨酰胺、丙氨酰谷氨酰胺或谷胱甘肽为有效量或总量计算],根据年龄、体重、疾病类型、疾病的症状程度等具体情况,每日分数次使用。
本组合物对人体健康无明显的副作用,符合社会需求,可以应用于工业生产。
下面结合实施例对发明的组合物的药理效果作进一步描述:
实施例1:
对吲哚美辛和乙醇诱发胃粘膜损伤的影响:
按Robert等的方法(Gastroenterology 1979;77:433),以乙酰谷氨酰胺(300mg/kg/d)和对乙酰氨基苯乙酸锌(100mg/kg/d)的组合物给大鼠灌胃三天,在最后一次给药前30分钟,以30mg/kg剂量的吲哚美辛灌胃,3小时后灌胃1ml的无水乙醇,再过1小时后处大鼠,测定所造成的溃疡长度。
按Robert等的方法(Gastroenterology 1979;77:433),以乙酰谷氨酰胺(300mg/kg/d)、对乙酰氨基苯乙酸锌(100mg/kg/d)、乙酰谷氨酰胺(300mgmg/kg/d)和对乙酰氨基苯乙酸锌(100mg/kg/d)的组合物给大鼠灌胃三天,在最后一次给药3小时后灌胃1ml的无水乙醇,再过1小时后处大鼠,测定所造成的溃疡长度。
表 对乙酰氨基苯乙酸锌和乙酰谷氨酰胺对吲哚美辛和乙醇诱发胃粘膜
损伤的影响[溃疡长度(mm)]
| 无水乙醇 | 无水乙醇+吲哚美辛 | ||||
| 空白组 | 组合物 | 空白组 | 对乙酰氨基苯乙酸锌 | 乙酰谷氨酰胺 | 组合物 |
| 73.1±17.5 | 16.3±4.4 | 120.9±18.2 | 51.3±14.9 | 39.4±7.9 | 26.7±5.7 |
Claims (1)
1.一种具有抗消化系统溃疡作用的药学可接受的组合物,其特征是含有锌化合物和谷氨酰胺类化合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97109039 CN1265799C (zh) | 1997-03-17 | 1997-03-17 | 含锌化合物和谷氨酰胺类的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97109039 CN1265799C (zh) | 1997-03-17 | 1997-03-17 | 含锌化合物和谷氨酰胺类的组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1166320A CN1166320A (zh) | 1997-12-03 |
| CN1265799C true CN1265799C (zh) | 2006-07-26 |
Family
ID=5170863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97109039 Expired - Fee Related CN1265799C (zh) | 1997-03-17 | 1997-03-17 | 含锌化合物和谷氨酰胺类的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1265799C (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011051742A1 (en) | 2009-10-28 | 2011-05-05 | Modutech S.A. | Preparation comprising amino acids and plants and its activity in the alcohol detoxification |
| CN102973541A (zh) * | 2011-09-02 | 2013-03-20 | 徐州医学院 | 一种l-瓜氨酸在制备抗胃溃疡药物中的应用 |
| CN105054068A (zh) * | 2014-01-25 | 2015-11-18 | 北京凯因科技股份有限公司 | 一种酵母谷胱甘肽营养配制品 |
| KR102094182B1 (ko) * | 2018-06-28 | 2020-03-30 | 주식회사 알랙스탠드 | 아연 함유 수용성 폴리글루타믹산 복합체 조성물 |
-
1997
- 1997-03-17 CN CN 97109039 patent/CN1265799C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1166320A (zh) | 1997-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goyal et al. | Asparagus racemosus-an update | |
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| WO2016062283A1 (zh) | 抗发炎用药物在制备抑制癌症的医药组合物中的应用 | |
| JPS6245535A (ja) | 鼻、口、舌下および膣腔の粘膜から薬剤を供給する吸収増強剤としてのアシルカルニチン類 | |
| EP0980245A1 (en) | Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction | |
| AU2003204391B2 (en) | Composition and its therapeutic use | |
| CN1265799C (zh) | 含锌化合物和谷氨酰胺类的组合物 | |
| CN1135178A (zh) | 用氧化氮合酶底物和/或供体,或者氧化氮抑制剂治疗子宫收缩疾病 | |
| EP3664786B1 (en) | Method for treating schnitzler's syndrome | |
| WO2024078507A1 (zh) | 麦角甾醇在制备防治胃溃疡药物中的应用 | |
| US5294440A (en) | Composition for treatment of cold sores | |
| CN1076195C (zh) | 含有锌化合物和对乙酰氨基苯乙酸的组合物 | |
| CN117425477A (zh) | 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物 | |
| RU2218172C1 (ru) | Способ лечения псориаза | |
| JP4370054B2 (ja) | 腸粘膜傷害の予防及び治療剤 | |
| Clifford et al. | Dimethyl myleran therapy combined with abdominal aortic occlusion | |
| WO2019128511A1 (zh) | 片仔癀及其制剂在制备治疗带状疱疹后遗神经痛的药物中的用途 | |
| US4537908A (en) | Herpes II treatment | |
| Capurso et al. | Cimetidine, 800 mg at night versus 400 mg twice daily, in the treatment of duodenal ulcer | |
| BRPI0902144A2 (pt) | processo para preparar uma composição farmacêutica sólida, de administração por via oral que contém os prìncipios ativos glicosamina e meloxicam e uso da associação entre glicosamina e meloxicam | |
| US6897239B1 (en) | Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women | |
| RU2294204C1 (ru) | Способ лечения язвенной болезни желудка и двенадцатиперстной кишки | |
| RU2106877C1 (ru) | Способ лечения идиопатического дерматомиозита | |
| US6525097B1 (en) | Method of treating a cancerous condition by enhancing the effectiveness of the human immune system | |
| CN120437267A (zh) | 沙丁鱼肽组合物在制备防治唇炎的药物中的新用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Xia Xiaolin Document name: patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Xia Xiaolin Document name: payment instructions |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |